A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Completed · Phase 1/Phase 2
Conditions studied: Solid Tumors, Breast Cancer, Cowden Syndrome
In brief
This is a phase I/II clinical research study with BGT226, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a Phase I dose escalation part followed by a safety expansion part and a Phase II expansion part. Once the MTD has been defined, the safety expansion and efficacy expansion parts of the trial will be opened for enrollment. Phase I safety expansion part will enroll advanced solid tumors. Phase II expansion part will enroll advanced breast cancer. An effort will be made to enrich the trial population with Cowden Syndrome patients with advanced solid malignancies.
Key facts
- Study ID
- NCT00600275
- Run by
- Novartis Pharmaceuticals
- People needed
- 57
- Starts
- 2007-12-01
- Last updated by the study team
- 2020-12-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients
- Histologically-confirmed, advanced solid tumors
- Progressive, recurrent unresectable disease
- Phase II expansion part (advanced breast cancer)
- Confirmed positive hormone receptor (estrogen receptor and/or progesterone receptor) or positive HER-2 expression status
- Disease progression/recurrence following hormonal or anti-HER-2 treatment for advanced disease
- At least one but not more than two prior chemotherapy regimens for the unresectable tumor
- Measurable disease by MRI or CT scan
- Cowden Syndrome patients with an advanced malignancy Genetic confirmation of Cowden Syndrome
- Age ≥ 18
- World Health Organization (WHO) Performance Status of ≤ 2
You may not qualify if…
- Hematopoietic:
- No diabetes mellitus or history of gestational diabetes mellitus
- No acute or chronic renal disease
- No acute or chronic liver disease
- No acute or chronic pancreatitis
- No impaired cardiac function or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension
- No acute myocardial infarction or unstable angina pectoris within the past 3 months
- Not pregnant or nursing and fertile patients must use barrier contraceptives
- Other protocol-defined inclusion/exclusion criteria may apply.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana Faber Cancer Institute — Boston, Massachusetts, United States
- Nevada Cancer Center — Las Vegas, Nevada, United States
- Cancer Therapy and Research Center (CTRC) — San Antonio, Texas, United States
- Princess Margaret Hospital — Toronto, Canada
- Novartis Investigative Site — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.